New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Mechelen, Belgium; 10 March 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by …